REAL‐WORLD OUTCOMES OF PATIENTS (PT) WITH RELAPSED OR REFRACTORY (R/R) CLL/SLL AND PRIOR TREATMENT (TX) WITH BOTH A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND VENETOCLAX.

Bibliographic Details
Published in:Hematological Oncology Vol. 41; pp. 733 - 735
Main Authors: Soumerai, J., Wang, L., Gu, F., Gu, T., Liu, F. F.
Format: Journal Article
Published: Wiley-Blackwell Jun2023 Supplement S2
Online Access:View this record in EBSCOhost